[EN] FLUORINATED PHENYLACETIC ACID DERIVATIVES IN A WEED CONTROL METHOD [FR] DÉRIVÉS D'ACIDE PHÉNYLACÉTIQUE FLUORÉS DANS UN PROCÉDÉ DE LUTTE CONTRE LES MAUVAISES HERBES
[EN] FLUORINATED PHENYLACETIC ACID DERIVATIVES IN A WEED CONTROL METHOD [FR] DÉRIVÉS D'ACIDE PHÉNYLACÉTIQUE FLUORÉS DANS UN PROCÉDÉ DE LUTTE CONTRE LES MAUVAISES HERBES
[EN] FLUORINATED PHENYLACETIC ACID DERIVATIVES IN A WEED CONTROL METHOD<br/>[FR] DÉRIVÉS D'ACIDE PHÉNYLACÉTIQUE FLUORÉS DANS UN PROCÉDÉ DE LUTTE CONTRE LES MAUVAISES HERBES
申请人:SYNGENTA CROP PROTECTION AG
公开号:WO2021094427A1
公开(公告)日:2021-05-20
The present invention relates to the use of a compound of Formula (I), wherein R1, R2 and n are as defined herein as a herbicide. The invention further relates to agrochemically acceptable salts, to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling weeds, in particular in crops of useful plants.
Optimizing Small Molecule Inhibitors of Calcium-Dependent Protein Kinase 1 to Prevent Infection by Toxoplasma gondii
作者:Sebastian Lourido、Chao Zhang、Michael S. Lopez、Keliang Tang、Jennifer Barks、Qiuling Wang、Scott A. Wildman、Kevan M. Shokat、L. David Sibley
DOI:10.1021/jm4001314
日期:2013.4.11
Toxoplasma gondii is sensitive to bulky pyrazolo [3,4-d] pyrimidine (PP) inhibitors due to the presence of a Gly gatekeeper in the essential calcium dependent protein kinase 1 (CDPK1). Here we synthesized a number of new derivatives of 3-methyl-benzyl-PP (3-MB-PP, or 1). The potency of PP analogues in inhibiting CDPK1 enzyme activity in vitro (low nM IC50 values) and blocking parasite growth in host cell monolayers in vivo (low mu M EC50 values) were highly correlated and occurred in a CDPK1-specific manner. Chemical modification of the PP scaffold to increase half-life in the presence of microsomes in vitro led to identification of compounds with enhanced stability while retaining activity. Several of these more potent compounds were able to prevent lethal infection with T. gondii in the mouse model. Collectively, the strategies outlined here provide a route for development of more effective compounds for treatment of toxoplasmosis and perhaps related parasitic diseases.